(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 3.96% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Johnson & Johnson's revenue in 2025 is $90,627,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2025 to be $224,959,942,876,641, with the lowest JNJ revenue forecast at $224,831,968,565,661, and the highest JNJ revenue forecast at $225,160,417,821,024. On average, 6 Wall Street analysts forecast JNJ's revenue for 2026 to be $234,043,525,175,280, with the lowest JNJ revenue forecast at $231,781,832,465,535, and the highest JNJ revenue forecast at $235,884,750,818,040.
In 2027, JNJ is forecast to generate $245,755,611,868,919 in revenue, with the lowest revenue forecast at $243,616,241,098,822 and the highest revenue forecast at $248,580,309,181,788.